By Bill Berkrot WASHINGTON (Reuters) - Amgen Inc's $14,000 cholesterol drug Repatha cut the risk of heart attack and stroke by over 20 percent in patients with heart disease, but results from a highly-anticipated study fell short of investor expectations and shares dropped 6 percent. The date unveiled on Friday demonstrated a clinical benefit beyond the drug's known ability to slash "bad" LDL cholesterol levels, but came in below high investor expectations.
More than 40 people including women and children have been shot dead aboard a boat carrying Somali refugees in the Red Sea off war-torn Yemen, officials said on Friday. The refugees were hit by light weapons fire in waters off rebel-held Hodeida, but the boat managed to dock in the city's port, an official there said. The International Organization for Migration, which has operations in Yemen, said 42 bodies had been recovered.
By Bill Berkrot WASHINGTON (Reuters) - Amgen Inc's $14,000 cholesterol drug Repatha cut the risk of heart attack and stroke by over 20 percent in patients with heart disease, but results from a highly-anticipated study fell short of investor expectations and shares dropped 6 percent. The date unveiled on Friday demonstrated a clinical benefit beyond the drug's known ability to slash "bad" LDL cholesterol levels, but came in below high investor expectations.
No comments:
Post a Comment